Pegavision (6491) - Net Assets
Based on the latest financial reports, Pegavision (6491) has net assets worth NT$11.74 Billion TWD (≈ $369.74 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$16.17 Billion ≈ $509.58 Million USD) and total liabilities (NT$4.44 Billion ≈ $139.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Pegavision to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$11.74 Billion |
| % of Total Assets | 72.56% |
| Annual Growth Rate | 21.68% |
| 5-Year Change | 113.05% |
| 10-Year Change | 857.68% |
| Growth Volatility | 32.74 |
Pegavision - Net Assets Trend (2012–2025)
This chart illustrates how Pegavision's net assets have evolved over time, based on quarterly financial data. Also explore 6491 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Pegavision (2012–2025)
The table below shows the annual net assets of Pegavision from 2012 to 2025. For live valuation and market cap data, see 6491 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$11.74 Billion ≈ $369.74 Million |
+6.12% |
| 2024-12-31 | NT$11.06 Billion ≈ $348.41 Million |
+10.81% |
| 2023-12-31 | NT$9.98 Billion ≈ $314.43 Million |
+53.88% |
| 2022-12-31 | NT$6.49 Billion ≈ $204.34 Million |
+17.74% |
| 2021-12-31 | NT$5.51 Billion ≈ $173.55 Million |
+19.86% |
| 2020-12-31 | NT$4.60 Billion ≈ $144.79 Million |
+13.37% |
| 2019-12-31 | NT$4.05 Billion ≈ $127.71 Million |
+101.89% |
| 2018-12-31 | NT$2.01 Billion ≈ $63.26 Million |
+36.83% |
| 2017-12-31 | NT$1.47 Billion ≈ $46.23 Million |
+19.75% |
| 2016-12-31 | NT$1.23 Billion ≈ $38.61 Million |
+17.54% |
| 2015-12-31 | NT$1.04 Billion ≈ $32.85 Million |
+13.89% |
| 2014-12-31 | NT$915.43 Million ≈ $28.84 Million |
+67.63% |
| 2013-12-31 | NT$546.10 Million ≈ $17.20 Million |
-40.35% |
| 2012-12-31 | NT$915.43 Million ≈ $28.84 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pegavision's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7759.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$5.82 Billion | 50.06% |
| Common Stock | NT$780.00 Million | 6.71% |
| Other Comprehensive Income | NT$823.69 Million | 7.08% |
| Other Components | NT$4.20 Billion | 36.15% |
| Total Equity | NT$11.63 Billion | 100.00% |
Pegavision Competitors by Market Cap
The table below lists competitors of Pegavision ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AUPU Home Style Corp Ltd
SHG:603551
|
$686.86 Million |
|
Sekerbank TAS
IS:SKBNK
|
$687.04 Million |
|
Argus Shanghai Textile Chemicals Co Ltd
SHG:603790
|
$687.17 Million |
|
Beijing Trust Far Tech
SHE:300231
|
$687.20 Million |
|
Investment AB Oresund
ST:ORES
|
$686.76 Million |
|
Covenant Logistics Group, Inc.
NYSE:CVLG
|
$686.50 Million |
|
WEB Travel Group Ltd
AU:WEB
|
$686.28 Million |
|
Corporación Actinver S. A. B. de C. V
MX:ACTINVRB
|
$686.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pegavision's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,966,407,000 to 11,631,150,000, a change of 664,743,000 (6.1%).
- Net income of 1,628,044,000 contributed positively to equity growth.
- Dividend payments of 858,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 843,450,999.
- Other factors decreased equity by 948,751,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$1.63 Billion | +14.0% |
| Dividends Paid | NT$858.00 Million | -7.38% |
| Other Comprehensive Income | NT$843.45 Million | +7.25% |
| Other Changes | NT$-948.75 Million | -8.16% |
| Total Change | NT$- | 6.06% |
Book Value vs Market Value Analysis
This analysis compares Pegavision's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.82x to 1.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | NT$21.80 | NT$279.50 | x |
| 2013-12-31 | NT$12.79 | NT$279.50 | x |
| 2014-12-31 | NT$16.89 | NT$279.50 | x |
| 2015-12-31 | NT$17.08 | NT$279.50 | x |
| 2016-12-31 | NT$20.00 | NT$279.50 | x |
| 2017-12-31 | NT$24.02 | NT$279.50 | x |
| 2018-12-31 | NT$32.71 | NT$279.50 | x |
| 2019-12-31 | NT$63.61 | NT$279.50 | x |
| 2020-12-31 | NT$64.42 | NT$279.50 | x |
| 2021-12-31 | NT$76.85 | NT$279.50 | x |
| 2022-12-31 | NT$89.87 | NT$279.50 | x |
| 2023-12-31 | NT$135.31 | NT$279.50 | x |
| 2024-12-31 | NT$139.24 | NT$279.50 | x |
| 2025-12-31 | NT$147.28 | NT$279.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pegavision utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.00%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 23.13%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.39x
- Recent ROE (14.00%) is below the historical average (14.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -3.82% | -15.20% | 0.15x | 1.72x | NT$-126.47 Million |
| 2013 | 8.17% | 7.58% | 0.57x | 1.89x | NT$-9.97 Million |
| 2014 | 7.53% | 7.49% | 0.59x | 1.72x | NT$-22.58 Million |
| 2015 | 12.19% | 9.72% | 0.76x | 1.65x | NT$22.85 Million |
| 2016 | 15.25% | 11.26% | 0.86x | 1.57x | NT$64.35 Million |
| 2017 | 20.64% | 13.88% | 0.75x | 1.98x | NT$156.16 Million |
| 2018 | 26.95% | 17.27% | 0.76x | 2.07x | NT$340.37 Million |
| 2019 | 11.73% | 14.17% | 0.63x | 1.31x | NT$70.12 Million |
| 2020 | 15.57% | 17.98% | 0.62x | 1.40x | NT$255.79 Million |
| 2021 | 22.76% | 22.32% | 0.65x | 1.56x | NT$699.97 Million |
| 2022 | 23.99% | 24.40% | 0.66x | 1.49x | NT$899.39 Million |
| 2023 | 16.71% | 24.39% | 0.49x | 1.40x | NT$665.13 Million |
| 2024 | 16.69% | 26.85% | 0.47x | 1.33x | NT$734.04 Million |
| 2025 | 14.00% | 23.13% | 0.44x | 1.39x | NT$464.93 Million |
Industry Comparison
This section compares Pegavision's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,650,883,600
- Average return on equity (ROE) among peers: 9.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pegavision (6491) | NT$11.74 Billion | -3.82% | 0.38x | $686.85 Million |
| St.Shine Optical Co Ltd (1565) | $966.82 Million | 24.11% | 0.40x | $164.40 Million |
| Maxigen Biotech Inc (1783) | $369.25 Million | -9.77% | 0.32x | $109.91 Million |
| SciVision Biotech Inc (1786) | $363.70 Million | 14.07% | 0.11x | $135.56 Million |
| Bioteque (4107) | $2.80 Billion | 15.38% | 0.38x | $252.17 Million |
| Chi Sheng Chemical (4111) | $1.05 Billion | 4.04% | 0.44x | $55.51 Million |
| BenQ Medical Technology (4116) | $1.09 Billion | 6.10% | 0.54x | $56.09 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.71 Billion | 14.28% | 0.40x | $181.84 Million |
| Bionime Corp (4737) | $2.54 Billion | 3.89% | 0.80x | $151.21 Million |
| Vizionfocus Inc. (4771) | $2.02 Billion | 15.48% | 0.59x | $347.59 Million |
| Formosa Optical Technology Co Ltd (5312) | $2.60 Billion | 6.55% | 1.44x | $183.92 Million |
About Pegavision
Pegavision Corporation manufactures and sells medical devices, and optical and precision instruments in Taiwan. It offers soft contact lenses. The company was founded in 2009 and is based in Taoyuan City, Taiwan. Pegavision Corporation is a subsidiary of Kinsus Interconnect Technology Corp.